The narrow road to expanded access

2024-9-1

Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients

2024-9-1

Shaping the Future Research Agenda of Cancer Nursing in Italy: Insights and Strategic Directions

2024-9-1

Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: A Population-based study of 154,863 patients

2024-9-1

Radiotherapy Resources in the Philippines: a 2022 update

2024-9-1

Global review of COVID-19 mitigation strategies and their impact on cancer service disruptions

2024-9-1

Pharmaceutical company funding of cancer patient advocacy organizations in the Netherlands

2024-9-1

Palliative Care in Turkey: Insights from Experts through Key Informant Interviews

2024-9-1

Inclusivity of patients in early phase breast cancer clinical trials.

2024-9-1

Is health-related quality of life sufficiently addressed in trials for breast cancer treatments? An assessment based on reimbursement opinions from the French health technology assessment body, 2009-2023

2024-9-1

Artificial Intelligence and cancer: profile of registered clinical trials

2024-9-1

Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer

2024-9-1

Corrigendum to “The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company” J. Cancer Policy. 40 (2024) 100473

2024-8-27

The productivity cost of mortality due to lung cancer, breast cancer and melanoma in Europe across 2010, 2015 and 2019

2024-8-1

Globalization of clinical research in oncology: status, challenges, and future directions

2024-8-1

A cross-sector approach to explore socio-ecological associations with treatment engagement behaviours in Northern Ghana

2024-7-25

Bridging Cancer Prevention Efforts: Georgia's Alignment with European Code Against Cancer

2024-7-1

Smoking and alcohol habits in head and neck cancers: how many patients stop after diagnosis?

2024-7-1

Whole genome sequencing as a ticket to cancer treatment in the Netherlands: Are inequalities in access to molecular diagnostics unfair?

2024-6-20

A review of factors influencing the uptake of prostate cancer treatment in Nigeria

2024-6-7

Social media engagement of supportive care publications in oncology

2024-6-7

Implementation of a nationwide population-level cancer screening in Bhutan: a programmatic experience

2024-6-6

Cancer Research Funding in South Asia

2024-6-6

Cervical cancer prevention in Southern Africa: a review of national cervical cancer screening guidelines in the Southern African Development Community

2024-6-1

Challenges of palliative care identified by stakeholders in resource-limited settings: A multi-regional study in Kazakhstan

2024-6-1

Socioeconomic disparities and health literacy: Unraveling the impact on diagnostic and cancer care in Uruguay

2024-6-1

Development of a rapid tool for screening financial toxicity based on the comprehensive score for financial toxicity

2024-6-1

Authorship Characteristics of Hematology and Oncology Education Chapters: A Comprehensive Analysis

2024-6-1

Corrigendum to: The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company. [Journal of Cancer Policy. 40 (2024):100473.]

2024-5-1

Implications of FDA’s Marketing Authorization of Hereditary Cancer Testing

2024-4-12

INDIGO: Example of inappropriate crossover and why PFS cannot be the primary outcome in gliomas

2024-4-6

Understanding Breast Cancer Patient Pathways and their impact on Survival in Mexico

2024-4-1

Sugar tax in Poland - bittersweet lessons three years after implementation

2024-4-1

Molecular Profiling of Brain Tumors in LMICs: Achievable or Impossible?

2024-4-1

Six country vignettes: Strengthening radiotherapy and theranostics

2024-3-29

HIV knowledge and information access among women cancer survivors in Nigeria

2024-3-1

The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: analysis of consumption of an Italian health care company

2024-3-1

Financial toxicity and its implication on quality of life in patients attending the palliative care department in a regional cancer centre: An observational study

2024-3-1

Cancer Advocacy in Residency Education: From principles to competencies

2024-3-1

Cancer care pathways across seven countries in Europe: What are the current obstacles? And how can artificial intelligence help?

2024-3-1

Roadmap to improve the organized cancer screening programs – The case of colorectal cancer screening in Montenegro

2024-3-1

The promise of POSIT: Real-world application of the Paediatric Oncology System Integration Tool

2024-3-1

Implementing the European code of cancer practice in rural settings

2024-3-1

Where are the inequalities in ovarian cancer care in a country with universal healthcare? A systematic review and narrative synthesis

2024-3-1

Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy

2024-3-1

Dealing with digital paralysis: Surviving a cyberattack in a National Cancer center

2024-3-1

Challenges in building radiotherapy capacity: A longitudinal study evaluating eight years of the Brazilian radiotherapy expansion plan

2024-3-1

The effectiveness of smoking cessation interventions after cancer diagnosis: A systematic review and meta-analysis

2024-3-1

Use of subjective minimizing language at hematology and oncology conferences: A systematic review

2024-3-1

Exploring the financial burden due to additional mobility among cancer patients: A cross-sectional study based on National Sample Survey

2024-3-1